MicroPort Scientific (HKSE:00853) Cash And Cash Equivalents : HK$7,962 Mil (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is MicroPort Scientific Cash And Cash Equivalents?

MicroPort Scientific's quarterly cash and cash equivalents declined from Dec. 2022 (HK$9,365.89 Mil) to Jun. 2023 (HK$6,606.59 Mil) but then increased from Jun. 2023 (HK$6,606.59 Mil) to Dec. 2023 (HK$7,962.49 Mil).

MicroPort Scientific's annual cash and cash equivalents declined from Dec. 2021 (HK$13,682.68 Mil) to Dec. 2022 (HK$9,365.89 Mil) and declined from Dec. 2022 (HK$9,365.89 Mil) to Dec. 2023 (HK$7,962.49 Mil).

MicroPort Scientific Cash And Cash Equivalents Historical Data

The historical data trend for MicroPort Scientific's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MicroPort Scientific Cash And Cash Equivalents Chart

MicroPort Scientific Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

2,185.86

7,768.00

13,682.68

9,365.89

7,962.49

MicroPort Scientific Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															13,682.68	10,836.64	9,365.89	6,606.59	7,962.49

MicroPort Scientific Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

MicroPort Scientific (HKSE:00853) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

MicroPort Scientific Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of MicroPort Scientific's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

MicroPort Scientific (HKSE:00853) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MicroPort Scientific Corp (HKSE:00853) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

MCRPF:USA MSK:Germany

Address

1601 Zhangdong Road, Zhangjiang Hi-Tech Park, Shanghai, CHN, 201203

Website

https://www.microport.com

MicroPort Scientific Corp develops & markets medical devices in eight segments. Cardiovascular devices business: sales, manufacture, R&D of cardiovascular devices like drug-eluting stents. Orthopedics devices business: sales, manufacture, R&D of orthopedics devices. CRM business: sales, manufacture, R&D of cardiac rhythm management devices. Endovascular & peripheral vascular devices business: sales, manufacture, R&D of endovascular & peripheral vascular devices. Neurovascular devices business: sales, manufacture, R&D of neurovascular devices. Heart valve business: sales, manufacture, R&D of heart valve devices. Surgical robot business: sales, manufacture, R&D of surgical robot devices. Surgical devices business: sales, manufacture, R&D of surgical devices. The key revenue is from The PRC.

Executives

Shang Hai Zhang Jiang Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Maxwell Maxcare Science Foundation Limited	2201 Interest of corporation controlled by you
We'tron Capital Limited	2101 Beneficial owner
Hillhouse Investment Management, Ltd.	2102 Investment manager
Hfty I Holdings Pte. Ltd.	2101 Beneficial owner
Otsuka Holdings Co., Ltd.
Otsuka Medical Devices Co., Ltd.
Hillhouse Capital Advisors, Ltd.	2102 Investment manager
Gaoling Fund, L.p.	2101 Beneficial owner

MicroPort Scientific (HKSE:00853) Headlines

No Headlines